Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia.
The efficacy of alpha interferon (IFN-alpha) in the treatment of severe type II essential mixed cryoglobulinemia (EMC) has been reported previously. In some patients, the development of neutralizing antibodies to recombinant IFN-alpha (rIFN-alpha) can affect the clinical response achieved with rIFN-alpha; a second treatment with natural IFN-alpha preparations may reinduce the clinical response. In the present study the ability of leukocyte IFN (LeIFN) to restore the response was investigated from a pharmacodynamic viewpoint. Specifically, the pharmacodynamic profiles of different IFN-alpha preparations were studied by measuring the serum neopterin levels and the levels of expression of protein MxA mRNA in in vivo peripheral blood mononuclear cells in two patients with EMC whose resistance to rIFN-alpha2a treatment increased concomitantly with the development of neutralizing antibodies. These markers were measured before injection and at 24 and 48 h after a single injection of rIFN-alpha2a, consensus IFN [(C)IFN], or LeIFN. No increase or only a slight increase in MxA mRNA levels was detectable after administration of rIFN-alpha2a or (C)IFN, whereas a significant increase (>/=10-fold) in MxA mRNA expression was recorded following administration of LeIFN. The neutralizing antibodies to rIFN-alpha2a cross-react with (C)IFN. Sera from these patients neutralized most but not all of the subtypes present in the natural IFN-alpha (LeIFN) mixture, and no significant increase in neopterin levels was observed after these patients were switched to LeIFN treatment. In summary, the data demonstrate that the problem of neutralizing antibodies still exists and that LeIFN may induce an increase in the level of MxA mRNA expression but not an increase in neopterin levels in patients who are resistant to treatment with rIFN-alpha2a or (C)IFN.
Scagnolari
Carolina
C
Department of Experimental Medicine, Virology Section, University La Sapienza Campus Biomedico, Libera Università, Rome, Italy.
Casato
Milvia
M
Bellomi
Francesca
F
De Pisa
Francesca
F
Turriziani
Ombretta
O
Coviello
Rossella
R
Pirro
Maria Rosaria
MR
Dianzani
Ferdinando
F
Antonelli
Guido
G
D000906:Antibodies / Q000097:blood; D015415:Biomarkers / Q000097:blood; D003449:Cryoglobulinemia / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D019204:GTP-Binding Proteins / Q000235:genetics; D006801:Humans; D016898:Interferon-alpha / Q000276:immunology* / Q000627:therapeutic use*; D007962:Leukocytes / Q000737:chemistry; D008297:Male; D008875:Middle Aged; D064547:Myxovirus Resistance Proteins; D019798:Neopterin / Q000097:blood; D012333:RNA, Messenger / Q000032:analysis; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use
D000906:Antibodies; D015415:Biomarkers; D016898:Interferon-alpha; C579071:MX1 protein, human; D064547:Myxovirus Resistance Proteins; D012333:RNA, Messenger; D011994:Recombinant Proteins; D019798:Neopterin; D019204:GTP-Binding Proteins